Post-stroke complications

Epidemiology and prospects for pharmacological intervention during rehabilitation

James F. Meschia, Askiel Bruno

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Stroke can be associated with a number of sequelae which require treatment during rehabilitation of the patient. These include aphasia, depression and emotionalism, central pain, spasticity and urinary incontinence. Patients will also require rehabilitation to optimise motor recovery. At present, no reliable evidence favours any drug for the treatment of aphasia or post-stroke urinary incontinence. On the basis of small, unconfirmed. randomised trials, a tentative recommendation can be made for the use of the antidepressants nortriptyline, citalopram, maprotiline or fluoxetine in post-stroke depression. and nortriptyline or citalopram in post-stroke emotionalism. The tricyclic antidepressant amitriptyline appears to be useful for the control of central post-stroke pain, and botulinum toxin A should be considered for post-stroke spasticity. Although limited data suggest that amphetamine and dexamphetamine can enhance motor recovery, these drugs remain investigational and their use cannot be recommended outside of clinical trials.

Original languageEnglish (US)
Pages (from-to)357-370
Number of pages14
JournalCNS Drugs
Volume9
Issue number5
DOIs
StatePublished - Jun 2 1998
Externally publishedYes

Fingerprint

Epidemiology
Rehabilitation
Stroke
Pharmacology
Nortriptyline
Citalopram
Aphasia
Urinary Incontinence
Maprotiline
Investigational Drugs
Depression
Pain
Dextroamphetamine
Type A Botulinum Toxins
Amitriptyline
Tricyclic Antidepressive Agents
Fluoxetine
Amphetamine
Antidepressive Agents
Clinical Trials

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Post-stroke complications : Epidemiology and prospects for pharmacological intervention during rehabilitation. / Meschia, James F.; Bruno, Askiel.

In: CNS Drugs, Vol. 9, No. 5, 02.06.1998, p. 357-370.

Research output: Contribution to journalReview article

@article{6d6eb7aaaf0e4633a1af145f74e382cf,
title = "Post-stroke complications: Epidemiology and prospects for pharmacological intervention during rehabilitation",
abstract = "Stroke can be associated with a number of sequelae which require treatment during rehabilitation of the patient. These include aphasia, depression and emotionalism, central pain, spasticity and urinary incontinence. Patients will also require rehabilitation to optimise motor recovery. At present, no reliable evidence favours any drug for the treatment of aphasia or post-stroke urinary incontinence. On the basis of small, unconfirmed. randomised trials, a tentative recommendation can be made for the use of the antidepressants nortriptyline, citalopram, maprotiline or fluoxetine in post-stroke depression. and nortriptyline or citalopram in post-stroke emotionalism. The tricyclic antidepressant amitriptyline appears to be useful for the control of central post-stroke pain, and botulinum toxin A should be considered for post-stroke spasticity. Although limited data suggest that amphetamine and dexamphetamine can enhance motor recovery, these drugs remain investigational and their use cannot be recommended outside of clinical trials.",
author = "Meschia, {James F.} and Askiel Bruno",
year = "1998",
month = "6",
day = "2",
doi = "10.2165/00023210-199809050-00003",
language = "English (US)",
volume = "9",
pages = "357--370",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "5",

}

TY - JOUR

T1 - Post-stroke complications

T2 - Epidemiology and prospects for pharmacological intervention during rehabilitation

AU - Meschia, James F.

AU - Bruno, Askiel

PY - 1998/6/2

Y1 - 1998/6/2

N2 - Stroke can be associated with a number of sequelae which require treatment during rehabilitation of the patient. These include aphasia, depression and emotionalism, central pain, spasticity and urinary incontinence. Patients will also require rehabilitation to optimise motor recovery. At present, no reliable evidence favours any drug for the treatment of aphasia or post-stroke urinary incontinence. On the basis of small, unconfirmed. randomised trials, a tentative recommendation can be made for the use of the antidepressants nortriptyline, citalopram, maprotiline or fluoxetine in post-stroke depression. and nortriptyline or citalopram in post-stroke emotionalism. The tricyclic antidepressant amitriptyline appears to be useful for the control of central post-stroke pain, and botulinum toxin A should be considered for post-stroke spasticity. Although limited data suggest that amphetamine and dexamphetamine can enhance motor recovery, these drugs remain investigational and their use cannot be recommended outside of clinical trials.

AB - Stroke can be associated with a number of sequelae which require treatment during rehabilitation of the patient. These include aphasia, depression and emotionalism, central pain, spasticity and urinary incontinence. Patients will also require rehabilitation to optimise motor recovery. At present, no reliable evidence favours any drug for the treatment of aphasia or post-stroke urinary incontinence. On the basis of small, unconfirmed. randomised trials, a tentative recommendation can be made for the use of the antidepressants nortriptyline, citalopram, maprotiline or fluoxetine in post-stroke depression. and nortriptyline or citalopram in post-stroke emotionalism. The tricyclic antidepressant amitriptyline appears to be useful for the control of central post-stroke pain, and botulinum toxin A should be considered for post-stroke spasticity. Although limited data suggest that amphetamine and dexamphetamine can enhance motor recovery, these drugs remain investigational and their use cannot be recommended outside of clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=0031748809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031748809&partnerID=8YFLogxK

U2 - 10.2165/00023210-199809050-00003

DO - 10.2165/00023210-199809050-00003

M3 - Review article

VL - 9

SP - 357

EP - 370

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 5

ER -